United Therapeutics Corporation Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value
United Therapeutics Corporation (UTHR) had Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value of $7.00 million as of 2016-09-30, per its 10-Q filed 2016-10-27.
Discontinued › Notes › Credit Losses › ASU 2016-13 Transition
us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2017-02-22
- 2016-09-30: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $7.00M.
- 2016-06-30: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $3.00M.
- 2016-03-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $18.50M.
- 2015-12-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value $111.90M; Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value as first filed $111.98M.
| Period end | Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value | Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value as first filed |
|---|---|---|
| 2016-09-30 | $7.00M 10-Q · filed 2016-10-27 | |
| 2016-06-30 | $3.00M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $18.50M 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $111.90M 10-K · filed 2017-02-22 | $111.98M 10-K · filed 2016-02-25 |
| 2015-09-30 | $33.43M 10-Q · filed 2015-10-27 | |
| 2015-06-30 | $39.78M 10-Q · filed 2015-07-28 | |
| 2015-03-31 | $24.65M 10-Q · filed 2015-04-28 | |
| 2014-12-31 | $105.56M 10-K · filed 2016-02-25 | |
| 2014-09-30 | $81.71M 10-Q · filed 2014-10-28 | |
| 2014-06-30 | $34.96M 10-Q · filed 2014-07-29 | |
| 2014-03-31 | $179.68M 10-Q · filed 2014-04-29 | |
| 2013-12-31 | $245.32M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $151.65M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $154.86M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $163.38M 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $163.69M 10-K · filed 2014-02-25 | |
| 2012-09-30 | $85.97M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $231.01M 10-Q · filed 2012-07-26 | |
| 2012-03-31 | $235.73M 10-Q · filed 2012-04-26 | |
| 2011-12-31 | $319.40M 10-K · filed 2013-02-26 | |
| 2011-09-30 | $338.08M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $160.74M 10-Q · filed 2011-07-28 | |
| 2010-12-31 | $260.73M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |